Camp4’s Pioneering SYNGAP-1 Drug Enters Toxicology Studies
CAMP4 Therapeutics has begun GLP toxicology studies for CMP-SYNGAP-01, an intrathecally delivered antisense oligonucleotide designed to upregulate SYNGAP1 expression...
Radiopharm Trial To Accelerate After Positive DSMC Review
After completing the initial 30 mCi cohort with acceptable safety, pharmacokinetics, and biodistribution, the Phase 1 HEAT study of...
New AML Clinical Trial Targets Dual NPM1 & FLT3 Mutations
Kura Oncology and Kyowa Kirin have dosed the first patient in a new cohort of the Phase 1b KOMET-007...
Comphya Implants First CaverStim Device in U.S. Pilot Study
A 20-patient, single-site U.S. pilot has begun enrolling at Johns Hopkins under an FDA IDE to evaluate the safety...
Nuwellis: 92% Survival in Kids with Kidney Injury, Failure
Topline: In a multicenter registry of 91 critically ill pediatric patients treated with the Aquadex ultrafiltration system, 92% survived...
Silexion Data Shows Powerful 99.7% KRAS Cancer Inhibition
Silexion reported new preclinical data showing its RNAi candidate SIL204 inhibited proliferation by 83.5% to 99.7% across 11 human...
Vivex RESTORE Trial: A New Hope for Degenerative Disc Disease
Vivex Biologics has dosed the first patient in Restore, a randomized, double‑blind, sham‑controlled U.S. trial of VIA Disc NP...
Compelling Cellectar Data: A Soaring Hope for Kids’ Cancer
In an interim readout from the Phase 1b CLOVER-2 study in relapsed/refractory pediatric high-grade glioma (pHGG), patients receiving at...
Reunion Doses First Patient in Phase 2 Cancer Trial
Reunion Neuroscience’s RECONNECT Phase 2 trial in postpartum depression met its primary endpoint with a clinically meaningful reduction in...
Kynexis Doses First Patient in Phase 2 Schizophrenia Trial
Phase 1 data for KYN-5356 showed an acceptable safety and tolerability profile, adequate CNS penetration, dose-dependent reductions of kynurenic...